MetaADEDB 2.0 @ LMMD
lixisenatide
(XVVOERDUTLJJHN-IAEQDCLQSA-N)
Structure
SMILES
NCCCC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)CCCCN)CCCCN)CCCCN)CCCCN)CCCCN)CCCCN)CO)C)CO)CO)CC(=O)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H](NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](NC(=O)[C@H]([C@H](O)C)NC(=O)CNC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc1nc[nH]c1)N)CCC(=O)O)Cc1ccccc1)CO)CC(=O)O)CC(C)C)CO)CCCCN)CCC(=O)N)CCSC)CCC(=O)O)CCC(=O)O)CCC(=O)O)C)CCCNC(=N)N)CC(C)C)Cc1ccccc1)CCC(=O)O)CC(C)C
Molecular Formula:
C215H347N61O65S
Molecular Weight:
4858.490
Log P:
2.1317
Hydrogen Bond Acceptor:
125
Hydrogen Bond Donor:
70
TPSA:
2085.46
CAS Number(s):
320367-13-3
Synonym(s)
1.
lixisenatide
2.
AQVE-10010
3.
AVE 0010
4.
AVE 010
5.
AVE-0010
6.
AVE-010
7.
AVE0010
8.
Adlyxin
9.
DES-38-proline-exendine-4 (Heloderma suspectum)-(1-39)-peptidylpenta-l-lysyl-l-lysinamide
10.
Lyxumia
11.
ZP 10
12.
ZP-10
13.
ZP10A peptide
External Link(s)
MeSHC479460
PubChem Compound131704318
90472060
16139342
ChEBI85662
DrugCentral4815
IUPHAR/BPS Guide to PHARMACOLOGY7387
Therapeutic Target DatabaseD05MKA
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1SinobronchitisFAERS: 1US FAERS
2Hyperplasia28213092CTD
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120331

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.